Athersys (NASDAQ:ATHX) versus IntelGenx Technologies (OTCMKTS:IGXT) Head to Head Contrast

Valuation and Earnings

This table compares IntelGenx Technologies and Athersys”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IntelGenx Technologies	$1.04 million	28.05	-$9.93 million	($0.06)	-2.78
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A

IntelGenx Technologies has higher revenue and earnings than Athersys. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IntelGenx Technologies has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the S&P 500.

Profitability

This table compares IntelGenx Technologies and Athersys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IntelGenx Technologies	N/A	N/A	N/A
Athersys	N/A	N/A	-223.03%

Insider & Institutional Ownership

19.4% of Athersys shares are owned by institutional investors. 42.0% of IntelGenx Technologies shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

IntelGenx Technologies beats Athersys on 6 of the 8 factors compared between the two stocks.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.